COA Releases Statement on President Trump's Blueprint to Lower Drug Prices

May 17, 2018

In response to President Donald Trump's blueprint on lowering drug prices and reducing out-of-pocket costs, Community Oncology Alliance (COA) commended the administration for working to put patients first and lower prices, while also urging caution for unintended consequences.

In response to President Donald Trump's blueprint on lowering drug prices and reducing out-of-pocket costs, Community Oncology Alliance (COA) commended the administration for working to put patients first and lower prices.

COA praised President Trump, HHS Secretary Alex Azar, CMS Administrator Seema Verma, and FDA Commissioner Scott Gottlieb, MD, for their work on addressing the abuses by pharmacy benefit managers, making adjustments to the 340B program, and increasing competition through the approval of new generic drugs.

While recognizing these efforts, COA also urged caution, noting that well-intended policy making can backfire and result in unintended consequences of increasing costs, harming patients, and limiting access to care.

Read the full press release here.